You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR RADIUM RA-223 DICHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for RADIUM RA-223 DICHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00699751 ↗ A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases Completed Bayer Phase 3 2008-06-01 ALSYMPCA (ALpharadin in SYMPtomatic Prostate CAncer) is an international Phase III clinical study to evaluate the efficacy and safety of Radium-223 dichloride in patients with hormone refractory prostate cancer and skeletal metastases.
NCT01516762 ↗ Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases No longer available Bayer 1969-12-31 This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC patients diagnosed with symptomatic bone metastasis and to collect additional short and long term safety data on the product.
NCT01618370 ↗ Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases Completed Bayer Phase 3 2012-07-22 This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with bone metastasis and to collect additional short and long term safety data on the product.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for RADIUM RA-223 DICHLORIDE

Condition Name

Condition Name for RADIUM RA-223 DICHLORIDE
Intervention Trials
Prostatic Neoplasms 7
Prostate Cancer 4
Bone Metastases 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for RADIUM RA-223 DICHLORIDE
Intervention Trials
Prostatic Neoplasms 25
Neoplasm Metastasis 8
Carcinoma 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for RADIUM RA-223 DICHLORIDE

Trials by Country

Trials by Country for RADIUM RA-223 DICHLORIDE
Location Trials
United States 251
Italy 75
United Kingdom 60
Germany 53
Spain 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for RADIUM RA-223 DICHLORIDE
Location Trials
California 17
New York 14
Pennsylvania 13
Michigan 12
Missouri 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for RADIUM RA-223 DICHLORIDE

Clinical Trial Phase

Clinical Trial Phase for RADIUM RA-223 DICHLORIDE
Clinical Trial Phase Trials
Phase 4 1
Phase 3 4
Phase 2 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for RADIUM RA-223 DICHLORIDE
Clinical Trial Phase Trials
Completed 12
Recruiting 10
Active, not recruiting 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for RADIUM RA-223 DICHLORIDE

Sponsor Name

Sponsor Name for RADIUM RA-223 DICHLORIDE
Sponsor Trials
Bayer 19
National Cancer Institute (NCI) 5
Affiliated Hospital of Jiangnan University 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for RADIUM RA-223 DICHLORIDE
Sponsor Trials
Industry 26
Other 19
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.